Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Operating income on consolidated basis increased by 38.10% at Rs 44.58 crore in Q4 FY25
Approximately 35% of male cancer patients and 12% of female cancer patients at Paras Health were diagnosed with tobacco-related cancers
The initiative was announced at World Hypertension Congress, Chennai
For FY25, Revenue from operation grew 28.8 per cent YoY to Rs. 70.1 crore
The company recorded its quarterly consolidated revenue from operations at Rs. 61.22 crore in Q4 FY25
The company was awarded the insulins supply contract for a three-year period in 2022 through April 2025
Enpatoran is a potential first-in-class oral therapy for CLE and SLE that is thought to selectively block the activation of Toll-like receptors (TLR)7 and TLR8
This global affiliation marks a critical step in the company’s mission to create long-term value through ethical practices, scientific innovation, and inclusive healthcare delivery
Subscribe To Our Newsletter & Stay Updated
